← Back to Analyst Consensus 
HRMY Buy
Harmony Biosciences Holdings, Inc.
Current Price —
Implied Upside —
Analysts 17
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 3 reiterations from 2 firms
Next Earnings
Nov 4, 2026 (8 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 19, 2026 | Needham | reiterate | Buy → Buy | — | 50% |
| Oct 13, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Oct 12, 2026 | Needham | reiterate | Buy → Buy | — | 50% |
| Aug 26, 2026 | Wolfe Research | initiate | — → Outperform | — | 54% |
| Aug 5, 2026 | Truist Securities | maintain | Hold → Hold | — | 54% |
| Aug 4, 2026 | Needham | maintain | Buy → Buy | — | 50% |
| Jul 31, 2026 | Mizuho | maintain | Outperform → Outperform | — | 52% |
| Jul 16, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Jun 30, 2026 | Deutsche Bank | maintain | Hold → Hold | — | 57% |
| May 8, 2026 | Truist Securities | maintain | Hold → Hold | — | 54% |
| Feb 25, 2026 | UBS | maintain | Neutral → Neutral | $36 | 54% |
| Feb 25, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | $55 | 44% |
| Feb 25, 2026 | B of A Securities | maintain | Underperform → Underperform | $28 | 53% |
| Feb 25, 2026 | Needham | maintain | Buy → Buy | $44 | 50% |
| Feb 11, 2026 | UBS | downgrade | Buy → Neutral | $46 | 54% |
| Jan 8, 2026 | Truist Securities | maintain | Buy → Buy | $45 | 54% |
| Dec 1, 2025 | Mizuho | maintain | Outperform → Outperform | $46 | 52% |
| Nov 24, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $55 | 44% |
| Nov 24, 2025 | Needham | reiterate | Buy → Buy | $42 | 50% |
| Nov 6, 2025 | Mizuho | maintain | Outperform → Outperform | $39 | 52% |
| Oct 15, 2025 | UBS | maintain | Buy → Buy | $43 | 54% |
| Sep 25, 2025 | Mizuho | maintain | Outperform → Outperform | $35 | 52% |
| Sep 25, 2025 | Deutsche Bank | maintain | Buy → Buy | $36 | 57% |
| Sep 25, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $55 | 44% |
| Sep 24, 2025 | Needham | maintain | Buy → Buy | $41 | 50% |
| Jul 21, 2025 | Truist Securities | initiate | — → Buy | $48 | 54% |
| Jul 10, 2025 | Deutsche Bank | maintain | Buy → Buy | $55 | 57% |
| May 15, 2025 | Mizuho | maintain | Outperform → Outperform | $48 | 52% |
| May 7, 2025 | Needham | reiterate | Buy → Buy | $49 | 50% |
| May 6, 2025 | Needham | reiterate | Buy → Buy | $49 | 50% |
| Apr 28, 2025 | UBS | maintain | Buy → Buy | $48 | 54% |
| Apr 10, 2025 | Needham | reiterate | Buy → Buy | $50 | 50% |
| Apr 8, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $70 | 44% |
| Apr 8, 2025 | Needham | reiterate | Buy → Buy | $50 | 50% |
| Mar 18, 2025 | Mizuho | maintain | Outperform → Outperform | $44 | 52% |
| Feb 27, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $70 | 44% |
| Feb 26, 2025 | Needham | reiterate | Buy → Buy | $50 | 50% |
| Feb 25, 2025 | Needham | reiterate | Buy → Buy | $50 | 50% |
| Feb 20, 2025 | Mizuho | maintain | Outperform → Outperform | $42 | 52% |
| Feb 19, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $75 | 44% |
| Feb 19, 2025 | Needham | maintain | Buy → Buy | $50 | 50% |
| Feb 11, 2025 | Deutsche Bank | initiate | — → Buy | $55 | 57% |
| Jan 27, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $75 | 44% |
| Jan 16, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $75 | 44% |
| Jan 13, 2025 | Needham | reiterate | Buy → Buy | $52 | 50% |
| Jan 13, 2025 | Oppenheimer | maintain | Outperform → Outperform | $61 | 52% |
| Dec 17, 2024 | HC Wainwright & Co. | initiate | — → Buy | $75 | 44% |
| Oct 30, 2024 | Cantor Fitzgerald | maintain | Overweight → Overweight | $58 | 50% |
| Oct 30, 2024 | Oppenheimer | reiterate | Outperform → Outperform | $59 | 52% |
| Oct 30, 2024 | Needham | reiterate | Buy → Buy | $52 | 50% |
Price Target Trend
Jun 6, 2026 Oct 27, 2026
EPS Estimates
0y —
0q —
+1y —
+1q —
Cross-Platform Signals
No cross-platform signals in the last 90 days